References
- Nelson DA, Davey FR. Erythrocytic disorders. In: Henry JB. (ed) Clinical diagnosis and management by laboratory methods, 17th edn. Philadelphia, PA: WB Saunders, 2001; 687-688.
- Dumaswala U, Zhuo L, Mahajan S et al. Glutathione protects chemokine-scavenging and antioxidative defense functions in human RBCs. Am J Physiol 2001; 280: C867–C873.
- Maxwell SR. Prospects for the use of antioxidant therapies. Drugs 1995; 49: 345–361.
- Dincer Y, Akcay T, Alademir Z, Ilkova H. Effect of oxidative stress on glutathione pathway in red blood cells from patients with insulin-dependent diabetes mellitus. Metabolism 2002; 51: 1360.
- Maritim A, Sanders R, Watkins III J. Diabetes, oxidative stress and antioxidants: a review. JBiochem Mol Toxicol 2003; 17: 24–38.
- Richards R, Roberts T, McGregor N, Dunstan R, Butt H. Blood parameters indicative of oxidative stress are associated with symptom expression in chronic fatigue syndrome. Redox Report 2000; 5: 35–41.
- Blankenberg S, Rupprecht HJ, Bickel C et al. Glutathione peroxidase 1 activity and cardiovascular events in patients with coronary artery disease. N Engl J Med 2003; 349: 1605–1613.
- de Haan JB, Crack PJ, Flentjar N, Iannello RC, Hertzog PJ, Kola I. An imbalance in antioxidant defense affects cellular function: the pathophysiological consequences of a reduction in antioxidant defense in glutathione peroxidase-1 (Gpx-1) knockout mouse. Redox Report 2003; 8: 69–79.
- Young I, Woodside J. Antioxidants in health and disease. J Clin Pathol 2001; 4: 176.
- Robertson R, Harmon J, Tran P, Tanaka Y, Takahashi H. Glucose toxicity in beta-cells: type 2 diabetes, good radicals gone bad and the glutathione connection. Diabetes 2003; 52: 581–587.
- Keenoy BM, Vertommen J, De Leeuw I. Divergent effects of different oxidants on glutathione homeostasis and protein damage in erythrocytes from diabetic patients: effects of high glucose. Mol Cell Biochem 2001; 225: 59–73.
- Vijayalingam S, Parthiban A, Shanmugasundaram KR, Mohan V. Abnormal antioxidant status in impaired glucose tolerance and non-insulin-dependent diabetes mellitus. Diabet Med 2004; 13: 715.
- Betteridge J. Long-term risk reduction: who needs treatment? In: Targeting dyslipidemia - the key to CHD risk reduction in the diabetic population 1. Report of annual meeting of the European Association for the Study of Diabetes, Munich, 2004.
- Festa A, Williams K, Hanley A et al. Pre-diabetes associated with lipid abnormalities. Circulation 2005; 111: 3465–3472.
- Hu FB, Stampfer MJ, Haffner SM, Solomon CG, Willett WC, Manson JE. Elevated risk of cardiovascular disease prior to clinical diagnosis of Type 2 diabetes. Diabetes Care 2002; 25: 1129–1134.
- Williams D, Cadwell B, Cheng Yet al. Prevalence of impaired fasting glucose and its relationship with cardiovascular disease risk factors in US adolescents, 1999-2000. Paediatrics 2005; 116: 1122.
- American Diabetes Association. Frequently Asked Questions about pre-diabetes. http://www.diabetes.org/pre-diabetes/faq.jsp. [Accessed 13 April 2006.
- Tirosh A, Shai I, Tekes-Manova D et al. Normal fasting plasma glucose levels and type 2 diabetes in young men. N Engl J Med 2005; 353: 1454.
- Banerjee M, Cruickshank JK. Prediabetes: is the term useful? Br J Diabetes Vasc Dis 2004; 4: 221–225.
- Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes 2005; 54: 1615–1625.
- DCCT Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977
- Baynes JW, Thorpe SR. Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. Diabetes 1999; 48: 1–9.
- Ceriello A, Motz E. Is oxidative stress the pathogenic mechanism underlying insulin resistance, diabetes, and cardiovascular disease? The common soil hypothesis revisited. Arterioscler Thromb Vasc Biol 2004; 24: 816–823.